Skip to main content

EULAR Best Abstracts - Day 2

Jun 04, 2021 1:22 pm

The second day of EULAR 2021 took a big leap in online content.  #EULAR2021 generated 2500 tweets yesterday. Here is a compilation (with links) of presentations were the “Best” as seen by our RheumNow faculty. 

  1. Dr Mariette on BEL+RTX combo phase 2 RCT in Sjogrens. Safety ok. Trend to improvement in ESSDAI and stimulated salivary flow. B-cell depletion in salivary gland biopsies   Abstr#OP0135   @RichardPAConway

  2. COAST-Y 2 yr results: In r- and nr-axSpA, IXE tx led to consistent & sustained long-term improvements in disease activity & QoL. No new safety signals. #POS0912 @uptotate

  3. Abstract #OP0137 TNFi use for at least 1 year decreased radiographic sacroiliitis progression  in early AxSpA in this ten year multicenter study of the German Spondyloarthritis Inception cohort (GESPIC).  This effect becomes evident  2-4 years after Tx.  @MeralElRamahiMD

  4. 5 cases of single-dermatome Herpes Zoster in 4 patients treated w/ UPA 15 mg QD for active AS in SELECT-AXIS 1  Medium starDo not forgot to vaccinate patients with 1st dose of Shingrix prior to starting a JAK-i. 2nd dose can be given after start of therapy.  OP0144 @MeralElRamahiMD

  5. Efficacy & Safety of UPA in AS, after 1yr from SELECT-AXIS 1 study? 187 bDMARD-naive, active AS pts w/ inadeq resp to NSAID. 82-85% txed w/ UPA 15mg QD achieved BASDAI50 or ASDAS LDA over 64 wks.  No new safety signals & ZERO VTE, MACE, TB, or deaths w/ UPA.  OP0144  @MeralElRamahiMD 

  6. Filgotinib showed a decrease in spinal inflammation of AS pts after 12 weeks!  Imaging- Subscores of the posterior elements, facet joints and vertebral bodies showed significant changes AND significant changes in spine fat, bone erosion or new bone formation. Abs#OP0141  @doctorRBC

  7. In the ESPOIR cohort of 813 RA followed for 10 years, polypharmacy  associated w/ less DAS28 ESR Remission at 5 (45.0% in vs. 56.3% (p=0.03)) and 10 yrs (32.5% vs. 67.5% (p=0.06)) BUT no longer significant when adjusted for comorbidities! #OP0098. @AurelieRheumo

Disclosures
The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×